Precision Medicine for Focal Segmental Glomerulosclerosis

Overview

Journal Kidney Res Clin Pract

Specialty Nephrology

Date 2024 Feb 7

PMID 38325863

Authors

Yi Xie

Fei Liu

Affiliations

Soon will be listed here.

Abstract

Focal segmental glomerulosclerosis (FSGS) is one of the common causes of nephrotic syndrome in adults and children worldwide. FSGS consists of a group of kidney diseases classified based on specific histopathological features. The current classification of FSGS makes it difficult to distinguish individual differences in pathogenesis, disease progression, and response to treatment. In recent years, the spread of next-generation sequencing, updates in biological techniques, and improvements of treatment have changed our understanding of FSGS. In this review, we will discuss the use of genetic testing in patients with FSGS, explore its clinical significance from a genetic identification perspective, and introduce several new biomarkers, that may help in the early diagnosis of FSGS and guide the development of specific or targeted therapies, so as to understand the biological characteristics in FSGS. This will certainly help develop more effective and safer treatments and advance precision medicine.

References

Zhang S, Breidenbach J, Russell B, George J, Haller S . CD40/CD40L Signaling as a Promising Therapeutic Target for the Treatment of Renal Disease. J Clin Med. 2020; 9(11). PMC: 7697100. DOI: 10.3390/jcm9113653. View

Trautmann A, Bodria M, Ozaltin F, Gheisari A, Melk A, Azocar M . Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. Clin J Am Soc Nephrol. 2015; 10(4):592-600. PMC: 4386250. DOI: 10.2215/CJN.06260614. View

Shoji J, Mii A, Terasaki M, Shimizu A . Update on Recurrent Focal Segmental Glomerulosclerosis in Kidney Transplantation. Nephron. 2020; 144 Suppl 1:65-70. DOI: 10.1159/000510748. View

Yao T, Udwan K, John R, Rana A, Haghighi A, Xu L . Integration of Genetic Testing and Pathology for the Diagnosis of Adults with FSGS. Clin J Am Soc Nephrol. 2019; 14(2):213-223. PMC: 6390925. DOI: 10.2215/CJN.08750718. View

Zhang W, Zhang C, Chen H, Li L, Tu Y, Liu C . Evaluation of microRNAs miR-196a, miR-30a-5P, and miR-490 as biomarkers of disease activity among patients with FSGS. Clin J Am Soc Nephrol. 2014; 9(9):1545-52. PMC: 4152819. DOI: 10.2215/CJN.11561113. View

Kara Eroglu F, Orhan D, Inozu M, Duzova A, Gulhan B, Ozaltin F . CD80 expression and infiltrating regulatory T cells in idiopathic nephrotic syndrome of childhood. Pediatr Int. 2019; 61(12):1250-1256. DOI: 10.1111/ped.14005. View

Ekulu P, Nkoy A, Adebayo O, Kazadi O, Aloni M, Arcolino F . A focus on the association of Apol1 with kidney disease in children. Pediatr Nephrol. 2020; 36(4):777-788. DOI: 10.1007/s00467-020-04553-z. View

Liu G, He L, Yang X, Tang L, Shi W, She J . MicroRNA-155-5p Aggravates Adriamycin-Induced Focal Segmental Glomerulosclerosis through Targeting Nrf2. Nephron. 2022; 147(2):108-119. DOI: 10.1159/000525233. View

Song X, Fang X, Tang X, Cao Q, Zhai Y, Chen J . COQ8B nephropathy: Early detection and optimal treatment. Mol Genet Genomic Med. 2020; 8(8):e1360. PMC: 7434746. DOI: 10.1002/mgg3.1360. View

10.

Genovese G, Friedman D, Ross M, Lecordier L, Uzureau P, Freedman B . Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010; 329(5993):841-5. PMC: 2980843. DOI: 10.1126/science.1193032. View

11.

Walsh L, Reilly J, Cornwall C, Gaich G, Gipson D, Heerspink H . Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design. Kidney Int Rep. 2021; 6(10):2575-2584. PMC: 8484122. DOI: 10.1016/j.ekir.2021.07.006. View

12.

Lee J, Yang J, Kronbichler A, Eisenhut M, Kim G, Lee K . Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis. J Immunol Res. 2019; 2019:5679518. PMC: 6476117. DOI: 10.1155/2019/5679518. View

13.

Hansrivijit P, Puthenpura M, Ghahramani N . Efficacy of abatacept treatment for focal segmental glomerulosclerosis and minimal change disease: A systematic review of case reports, case series, and observational studies . Clin Nephrol. 2020; 94(3):117-126. DOI: 10.5414/CN110134. View

14.

Yildirim D, Bender O, Karagoz Z, Helvacioglu F, Bilgic M, Akcay A . Role of autophagy and evaluation the effects of microRNAs 214, 132, 34c and prorenin receptor in a rat model of focal segmental glomerulosclerosis. Life Sci. 2021; 280:119671. DOI: 10.1016/j.lfs.2021.119671. View

15.

Bukosza E, Kornauth C, Hummel K, Schachner H, Huttary N, Krieger S . ECM Characterization Reveals a Massive Activation of Acute Phase Response during FSGS. Int J Mol Sci. 2020; 21(6). PMC: 7139641. DOI: 10.3390/ijms21062095. View

16.

Savin V, Sharma M, Zhou J, Gennochi D, Fields T, Sharma R . Renal and Hematological Effects of CLCF-1, a B-Cell-Stimulating Cytokine of the IL-6 Family. J Immunol Res. 2015; 2015:714964. PMC: 4471311. DOI: 10.1155/2015/714964. View

17.

Trachtman H, Nelson P, Adler S, Campbell K, Chaudhuri A, Derebail V . DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. J Am Soc Nephrol. 2018; 29(11):2745-2754. PMC: 6218860. DOI: 10.1681/ASN.2018010091. View

18.

Saleem M . What is the Role of Soluble Urokinase-Type Plasminogen Activator in Renal Disease?. Nephron. 2018; 139(4):334-341. DOI: 10.1159/000490118. View

19.

Drovandi S, Lipska-Zietkiewicz B, Ozaltin F, Emma F, Gulhan B, Boyer O . Oral Coenzyme Q10 supplementation leads to better preservation of kidney function in steroid-resistant nephrotic syndrome due to primary Coenzyme Q10 deficiency. Kidney Int. 2022; 102(3):604-612. DOI: 10.1016/j.kint.2022.04.029. View

20.

Fan X, Yang H, Kumar S, Tumelty K, Pisarek-Horowitz A, Rasouly H . SLIT2/ROBO2 signaling pathway inhibits nonmuscle myosin IIA activity and destabilizes kidney podocyte adhesion. JCI Insight. 2016; 1(19):e86934. PMC: 5111509. DOI: 10.1172/jci.insight.86934. View